



## Mr. Patrick VRIJLANDT, Netherlands

Patrick Vrijlandt represents the Netherlands as an alternate member of the Committee for Human Medicinal Products (CHMP) at the European Medicines Agency (EMA) in Amsterdam since 2023. Previously, he joined the Medicines Evaluation Board in 2013, and was primarily involved in the assessment of scientific advices and marketing authorization applications for cardiovascular and metabolic products. He is vice-chair of EMA's cardiovascular working party.

He studied medicine in Groningen and became an internist in 2001. He further specialized in infectious diseases in Nijmegen. His clinical experience from working in small, large and academic hospitals primarily includes cardiovascular and intensive care medicine, diabetes and care for elderly patients. Before joining the MEB, he worked at a clinical pharmacology unit specializing in phase 1 and 2 drug development.